乙基3-[(6-{[乙氧基(羰基)乙酰基]氨基}嘧啶-4-基)硫烷基]丙酸酯 | 75139-06-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 乙基3-[(6-{[乙氧基(羰基)乙酰基]氨基}嘧啶-4-基)硫烷基]丙酸酯
• 中文别名: 替曲那新
• 英文名称: 3-hydroxy-4-[(2S)-2-[(1S,2S,6R)-2-[(E)-3-hydroxy-2-[(2R,3R,6S)-6-[(E,3S)-3-[(2R,3S,5R)-5-[(1S)-1-methoxyethyl]-3-methyloxolan-2-yl]but-1-enyl]-3-methyloxan-2-yl]prop-1-enyl]-6-methylcyclohexyl]propanoyl]-2H-furan-5-one
• CAS: 75139-06-9
• 化学式: C₃₅H₅₄O₈
• 分子量: 602.8
• InChiKey: BJUFZCRLMQPLMO-RHKPWOOXSA-N

物化性质

• LogP：
  3.603 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  43
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Novel erythromycin derivatives
  申请人：Pfizer Inc.

  公开号：US20040067897A1

  公开（公告）日：2004-04-08

  The invention relates to novel erythromycin derivatives, particularly ones with novel C-13 R 13 substitutents, and to pharmaceutically acceptable salts thereof. The compounds of this invention are useful as antibacterial agents and antiprotozoa agents and for other applications (e.g., anticancer, atherosclerosis, gastric motility reduction, etc.) in mammals, including man, as well as in fish and. The invention also relates to pharmaceutical compositions containing such compounds and to methods of treating bacterial protozoa infections by administering such compounds. The invention also relates to methods of preparing such compounds and to intermediates useful in such preparation.

  该发明涉及新型红霉素衍生物，特别是具有新型C-13 R13取代基的红霉素衍生物，以及其药用盐。本发明的化合物可用作抗菌剂和抗原虫剂以及在哺乳动物（如人类）、鱼类等中的其他应用（例如，抗癌、动脉粥样硬化、胃动力减弱等）。该发明还涉及含有这种化合物的药物组合物，以及通过给予这种化合物来治疗细菌原虫感染的方法。该发明还涉及制备这种化合物的方法以及在制备中有用的中间体。
• [EN] THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：SPROTT KEVIN

  公开号：WO2013103993A1

  公开（公告）日：2013-07-11

  Salinomycin analogs and pharmaceutically acceptable compositions containing salinomycin analogs. Dosage forms and kits comprising salinomycin analogs and pharmaceutically acceptable compositions containing salinomycin analogs. Methods of using salinomycin analogs, pharmaceutically acceptable compositions, dosage forms, and kits for the treatment of proliferative diseases, e.g., cancer, or microbial infections in a subject

  萨利诺霉素类似物及含有萨利诺霉素类似物的药物可接受组成物。包含萨利诺霉素类似物的剂型和套件以及含有萨利诺霉素类似物的药物可接受组成物。使用萨利诺霉素类似物，药物可接受组成物，剂型和套件的方法，用于治疗增生性疾病，如癌症，或受体内微生物感染。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Method of immobilizing membrane-associated molecules
  申请人：Brennan D. John

  公开号：US20050032246A1

  公开（公告）日：2005-02-10

  The present invention relates to methods of immobilizing membrane-associated molecules within a sol-gel matrix. The membrane-associated molecule is embedded in the bilayer of a liposome. The molecule-liposome assembly remains functionally intact when it is immobilized within a protein and membrane-compatible sol-gel derived from polyol silane precursors or sodium silicate. The activity and stability of the entrapped membrane-associated molecule was significantly improved in macroporous silica.

  本发明涉及将膜相关分子固定在溶胶-凝胶基质中的方法。膜相关分子被嵌入到脂质体的双层中。当分子-脂质体组装体被固定在由聚醇硅烷前体或硅酸钠制成的蛋白质和膜兼容性溶胶-凝胶中时，组装体仍然保持功能完整。在大孔径硅胶中，被困住的膜相关分子的活性和稳定性得到了显着提高。
• METHOD OF IMMOBILIZING MEMBRANE-ASSOCIATED MOLECULES
  申请人：Brennan John D.

  公开号：US20080261825A1

  公开（公告）日：2008-10-23

  The present invention relates to methods of immobilizing membrane-associated molecules within a sol-gel matrix. The membrane-associated molecule is embedded in the bilayer of a liposome. The molecule-liposome assembly remains functionally intact when it is immobilized within a protein and membrane-compatible sol-gel derived from polyol silane precursors or sodium silicate. The activity and stability of the entrapped membrane-associated molecule was significantly improved in macroporous silica.

  本发明涉及将膜相关分子固定在溶胶-凝胶基质中的方法。膜相关分子嵌入了脂质体的双层中。当分子-脂质体组装体被固定在由聚醇硅烷前体或硅酸钠制备的蛋白质和膜兼容性溶胶-凝胶中时，该组装体仍然功能完整。在大孔径硅胶中，包埋的膜相关分子的活性和稳定性得到了显著改善。